Therefore, these data suggest a paradigm shift for individuals experiencing clinical progression of pulmonary sarcoidosis: restoration of CD4+ T cell immune function would be a more effective treatment strategy to promote disease resolution. Here, CD4 is linked to pulmonary sarcoidosis.